Innate-adaptive IFN cross-talk reprograms myeloid and T cells for antitumor immunity with a second-generation recombinant MVA
S. Liu, Y. Wang, G. Mazo, S. Baseer Tariq, J. Angulo-Lozano, N. Yang, T. Zhang, Y. Wang, D. Hirschhorn, L. Ji, A. Tan, J. Wang, W. Yan, J. Choi, J. Z. Xiang, , L. Deng
This paper describes a second-generation recombinant MVA vaccine that enhances antitumor immunity by reprogramming myeloid and T cells through innate-adaptive IFN cross-talk.
bioRxiv · Sep 25, 2022 · PreprintImmunology